Q-omics provides the consensus-scored PDCD6IPP1 profile across patient tissues and cancer cell-line models. PDCD6IPP1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LAML. Among the 18 cancer types available for tumor–normal comparison, PDCD6IPP1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PDCD6IPP1 RNA expression shows 13,994 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LAML, KIRC, and THYM as cancer lineages where PDCD6IPP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDCD6IPP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDCD6IPP1 survival associations across molecular data types. PDCD6IPP1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDCD6IPP1 RNA expression–survival associations across cancer types. High PDCD6IPP1 expression shows unfavorable associations in LAML, LGG, BRCA, DLBC and CESC, but favorable associations in LIHC. The LAML Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LAML as the clearest survival context for PDCD6IPP1 RNA expression.
This table summarizes PDCD6IPP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PDCD6IPP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDCD6IPP1 shows lower tumor expression in KIRC, COAD, STAD, LUSC, UCEC and READ. The KIRC box plot shows higher PDCD6IPP1 RNA expression in normal versus tumor tissue (log2 FC = −0.508, t-test p < 0.001).
This table shows molecular features associated with PDCD6IPP1 in patient tissues and cancer cell lines. In patient samples, PDCD6IPP1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
